A5036798940- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Prostate Cancer Diagnosis and Treatment
- Mass Spectrometry Techniques and Applications
- Meningioma and schwannoma management
- Glioma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Nonmelanoma Skin Cancer Studies
- Cancer and Skin Lesions
- Peptidase Inhibition and Analysis
- Medical Imaging and Pathology Studies
- Pituitary Gland Disorders and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Neuroendocrine Tumor Research Advances
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Radiation Dose and Imaging
- Advanced Radiotherapy Techniques
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Management of metastatic bone disease
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Brain Metastases and Treatment
Cornell University
2015-2025
Weill Cornell Medicine
2017-2025
New York Hospital Queens
2011-2025
NewYork–Presbyterian Hospital
2011-2025
Presbyterian Hospital
2011-2025
Lenox Hill Hospital
2025
NewYork–Presbyterian Brooklyn Methodist Hospital
2025
Pontificia Universidad Javeriana
2025
The Netherlands Cancer Institute
2024
Penn Presbyterian Medical Center
2023
Abstract Purpose: To assess the efficacy of a single infusion radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (lutetium-177; 177Lu) by prostate-specific (PSA) decline, measurable disease response, and survival. Experimental Design: In this dual-center phase II study, two cohorts with progressive metastatic castration-resistant prostate cancer received one dose 177Lu-J591 (15 patients at 65 mCi/m2, 17 70 mCi/m2) radionuclide imaging. Expansion cohort (n =...
Black men are more likely to die of prostate cancer than white men. In with similar stages disease, the contribution biological vs nonbiological differences this observed disparity is unclear.To quantify association black race long-term survival outcomes after controlling for known prognostic variables and access care among cancer.This multiple-cohort study included updated individual patient-level data clinical T1-4N0-1M0 from following 3 cohorts: Surveillance, Epidemiology, End Results...
<h3>Importance</h3> Although poorly understood, there is heterogeneity in the molecular biology of cancer across race and ethnicities. The representation racial minorities large genomic sequencing efforts unclear, could have an impact on health care disparities. <h3>Objective</h3> To determine distribution among samples sequenced within Cancer Genome Atlas (TCGA) deficit needed to detect moderately common mutational frequencies minorities. <h3>Design, Setting, Participants</h3> This was a...
Here we aim to provide updated guidance and standards for the indication, acquisition, interpretation of PSMA PET/CT prostate cancer imaging. Procedures characteristics are reported a variety available small radioligands. Different scenarios clinical use PSMA-ligand discussed. This document provides clinicians technicians with best evidence, support implementation imaging in research routine practice.
Standard imaging for assessing osseous metastases in advanced prostate cancer remains focused on altered bone metabolism and is inadequate diagnostic, prognostic, or predictive purposes. We performed a first-in-human phase I/II study of (89)Zr-DFO-huJ591 ((89)Zr-J591) PET/CT immunoscintigraphy to assess performance characteristics detecting compared with conventional modalities (CIM) pathology.Fifty patients progressive metastatic castration-resistant cancers were injected 5 mCi (89)Zr-J591....
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified PSMA PET imaging. Promising results PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations targeting molecules radiolabels. Definitive evidence safety efficacy [177Lu]Lu-PSMA-617 combination standard-of-care has demonstrated metastatic...
Abstract Despite recent advances, advanced prostate cancer is suboptimally responsive to current chemotherapeutic agents. Radiolabeled monoclonal antibody therapy that targets prostate‐specific membrane antigen (PSMA) shows promise and an area of active investigation. J591 a deimmunized IgG developed target the extracellular domain PSMA. Preclinical early phase clinical studies using radiolabeled have demonstrated efficacy in targeting tumor cells decreasing levels antigen. well‐tolerated,...
Prostate-specific membrane antigen (PSMA) is a well-established target for developing radiopharmaceuticals imaging and therapy of prostate cancer (PCa). We have recently reported that novel <sup>99m</sup>Tc-labeled small-molecule PSMA inhibitors bind with high affinity to PSMA-positive tumor cells in vitro localize PCa xenografts. This study reports the first, our knowledge, human data men metastatic healthy male subjects. <b>Methods:</b> Under an exploratory investigational new drug, using...
Although guidelines such as those of the National Comprehensive Cancer Network consider (18)F-FDG PET/CT for systemic staging newly diagnosed stage III breast cancer patients, factors in addition to may influence utility PET/CT. Because invasive lobular carcinoma (ILC) is less conspicuous than ductal (IDC) on PET, we hypothesized that tumor histology be one factor. We evaluated patients with ILC compared IDC.In this Institutional Review Board-approved retrospective study, our Hospital...
Abstract In contrast to normal cells, cancer cells avidly take up glucose and metabolize it lactate even when oxygen is abundant, a phenomenon referred as the Warburg effect. This fundamental alteration in metabolism enables their specific detection by positron emission tomography (PET) following i.v. injection of analogue 18F-fluorodeoxy-glucose (18FDG). However, this useful imaging technique limited fact that not all cancers FDG. To identify molecular determinants 18FDG retention, we...
African-American men have the highest incidence of and mortality from prostate cancer. Whether a biological basis exists for this disparity remains unclear. Exome sequencing (
Background Prostate cancer is radiosensitive. Prostate‐specific membrane antigen (PSMA) selectively overexpressed on advanced, castration‐resistant tumors. Lutetium‐177–labeled anti‐PSMA monoclonal antibody J591 ( 177 Lu‐J591) targets prostate with efficacy and dose‐response/toxicity data when delivered as a single dose. Dose fractionation may allow higher doses to be administered safely. Method Men metastatic refractory or refusing standard treatment options normal neutrophil platelet...
Androgen receptor-signaling inhibitor (ARSi) drugs prolong life in metastatic castration-resistant prostate cancer (mCRPC), but such tumors eventually become resistant and progress. Comprehensive positron emission tomography/computed tomography (PET/CT) imaging using fluoro-2-D-deoxyglucose F 18 ([18F]-FDG) for glycolysis (Glyc) fluorodihydrotestosterone ([18F]-FDHT) androgen receptor (AR) expression determine heterogeneity of phenotypes, which may be useful distinguishing patients who will...
Meningiomas are the most common primary intracranial tumors, typically treated with surgery and adjuvant radiation in cases of subtotal resection and/or higher histopathologic grade. Contrast-enhanced magnetic resonance imaging (MRI) is gold standard for postoperative assessment treatment planning. However, MRI can have limited accuracy particularly presence posttreatment change. [68Ga]-DOTATATE a Positron Emission Tomography (PET) radiotracer targeting somatostatin receptor 2A (SSTR2A)....
PURPOSE Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface overexpressed PC, provides validated target. This dose-escalation study investigated the safety, efficacy, maximum tolerated dose (MTD), and recommended phase II (RP2D) for 225 Ac-J591, anti-PSMA monoclonal antibody J591 radiolabeled with alpha emitter actinium-225. METHODS Following investigational new drug-enabling...
ABSTRACT BACKGROUND AND PURPOSE Evidence from animal models and examination of human epilepsy surgery specimens indicates that inflammation plays an important role in epilepsy. Positron emission tomography (PET) using [C11]PK11195, a marker activated microglia, provides means to visualize neuroinflammation vivo humans. We hypothesize patients with active epilepsy, [C11]PK11195 PET (PK‐PET) may be able identify areas focally increased corresponding the seizure onset zone. METHODS A young...
In this pilot study we explored the feasibility of (89)Zr labeled J591 monoclonal antibody positron emission tomography localized prostate cancer.Before scheduled radical prostatectomy 11 patients were injected intravenously with (89)Zr-J591, followed 6 days later by whole body tomography. Patients underwent surgery day after imaging. Specimens imaged ex vivo micro and a custom 3 Tesla magnetic resonance scanner coil. Positron images histopathology correlated.Median patient age was 61 years...